Xoma Royalty Effe (XOMA) Stock
Small biotech company developing and licensing antibody treatments. Here's the price, business snapshot, and what's worth knowing about Xoma Royalty Effe in September 2026.
XOMA Corp (XOMA) is a small-cap biotechnology company best known for developing and licensing antibody-based therapeutics. The firm focuses on identifying promising antibody candidates and advancing them through early clinical development or partnering them with larger biopharma companies for further development and commercialisation. Its market value reflects both potential upside from clinical or licensing milestones and the typical risks faced by development-stage biotechs: regulatory setbacks, trial results, and financing needs. Investors should note XOMA’s reliance on partnerships and milestone-driven revenues, which can make cash flow lumpy. As with any biotech, share-price volatility can be high and outcomes binary; thorough research into the pipeline, recent news, and balance-sheet strength is essential. This summary is general educational information only and not personalised investment advice. Consider whether a small-cap, higher-risk biotech fits your objectives and risk tolerance before investing.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying XOMA's stock, predicting its value could rise significantly to $68.
Financial Health
XOMA is generating decent revenue and cash flow, but its profitability is modest.
Dividend
XOMA's projected dividend yield of 2.12% provides a modest income for investors. If you invested $1000 you would be paid $21.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Progress or setbacks in trials and licensing milestones can sharply affect valuation, though outcomes are uncertain and can be binary.
Partner Collaborations
XOMA’s strategy relies on partnerships to advance and commercialise candidates, which can reduce development costs but add dependency on third parties.
Small‑cap Volatility
Market moves can be abrupt and driven by news; the stock may suit growth-focused investors who accept higher risk and financing uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
